

**Table S2** - Evaluation of lymphocyte and macrophage scores in relation to therapy for GPA.

<b>Variables</b>	<b>Groups</b>		
<b>Presence or absence of therapy</b>	<b>Therapy (n=13)</b>	<b>No therapy (n=22)</b>	<b>p</b>
CD3, %	7.4 (6.2-10.8)	7.3 (4.9-15.7)	0.785
CD20, %	5.7 (2.7-8.0)	3.9 (1.8-9.9)	0.290
CD68, %	8.3 (6.8-17.3)	9.2 (6.0-19.5)	0.946
CD86, %	16.0 (7.4-26.9)	20.0 (10.4-38.6)	0.339
CD163, %	30.7 ± 15.2	37.9 ± 17.2	0.224
<b>Co-trimoxazol in patients with positive nose culture for <i>S aureus</i></b>	<b>Co-trimoxazol (n=7)</b>	<b>No co-trimoxazol (n=12)</b>	<b>p</b>
CD3, %	13.4 ± 11.9	11.2 ± 5.0	0.575
CD20, %	2.5 (1.9-4.3)	6.2 (3.0-9.6)	0.117
CD68, %	6.3 (5.1-13.3)	13.4 (6.6-18.7)	0.083
CD86, %	18.2 (8.3-23.9)	18.7 (6.3-38.7)	0.966
CD163, %	31.1 ± 12.8	35.2 ± 16.5	0.585
<b>Co-trimoxazol in patients with negative nose culture for <i>S aureus</i></b>	<b>Co-trimoxazol (n=7)</b>	<b>No co-trimoxazol (n=8)</b>	<b>p</b>
CD3, %	5.1 (3.6-8.9)	6.2 (4.9-7.2)	0.778
CD20, %	7.7 ± 7.9	4.1 ± 3.5	0.271
CD68, %	9.6 (8.6-20.7)	8.1 (7.3-28.1)	0.778
CD86, %	23.4 (13.0-40.7)	18.8 (11.2-24.4)	0.535
CD163, %	34.4 ± 14.3	39.9 ± 23.5	0.601
<b>Use of prednisolone</b>	<b>Prednisolone (n=10)</b>	<b>No prednisolone (n=25)</b>	<b>p</b>
CD3, %	5.4 (4.3-9.8)	8.0 (6.2-14.8)	0.068
CD20, %	5.6 (1.8-10.9)	4.0 (2.5-7.4)	0.827
CD68, %	15.1 (6.7-26.4)	8.3 (6.3-14.8)	0.144
CD86, %	23.7 (12.4-41.3)	18.2 (8.1-24.2)	0.243
CD163, %	43.7 ± 20.2	31.8 ± 14.0	0.055

Data are presented as mean and standard deviation or as median and interquartile range.